Enanta Pharmaceuticals, Inc.2025财年第一财季实现净利润-22.64百万美元，同比增加27.34%

市场透视2025-05-19

5月19日，Enanta Pharmaceuticals, Inc.（ENTA.US）公布财报，公告显示公司2025财年第一财季净利润为-22.64百万美元，同比增加27.34%；其中营业收入为14.93百万美元，同比减少12.43%，每股基本收益为-1.06美元。从资产负债表来看，Enanta Pharmaceuticals, Inc.（ENTA.US）总负债2.29亿美元，其中短期债务...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2536459445?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-19 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2536459445","market":"us","top_or_hot":-1,"title":"Enanta Pharmaceuticals, Inc.2025财年第一财季实现净利润-22.64百万美元，同比增加27.34%","media":"市场透视","content":"<div>\n<p>5月19日，Enanta Pharmaceuticals, Inc.（ENTA.US）公布财报，公告显示公司2025财年第一财季净利润为-22.64百万美元，同比增加27.34%；其中营业收入为14.93百万美元，同比减少12.43%，每股基本收益为-1.06美元。从资产负债表来看，Enanta Pharmaceuticals, Inc.（ENTA.US）总负债2.29亿美元，其中短期债务...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000234a482f04f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enanta Pharmaceuticals, Inc.2025财年第一财季实现净利润-22.64百万美元，同比增加27.34%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnanta Pharmaceuticals, Inc.2025财年第一财季实现净利润-22.64百万美元，同比增加27.34%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-19 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000234a482f04f&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月19日，Enanta Pharmaceuticals, Inc.（ENTA.US）公布财报，公告显示公司2025财年第一财季净利润为-22.64百万美元，同比增加27.34%；其中营业收入为14.93百万美元，同比减少12.43%，每股基本收益为-1.06美元。从资产负债表来看，Enanta Pharmaceuticals, Inc.（ENTA.US）总负债2.29亿美元，其中短期债务...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000234a482f04f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ENTA","symbol_name":"Enanta Pharmaceuticals Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000234a482f04f&s=b","article_id":"2536459445","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000234a482f04f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2536459445","pubTimestamp":1747584049,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月19日，Enanta Pharmaceuticals, Inc.公布财报，公告显示公司2025财年第一财季净利润为-22.64百万美元，同比增加27.34%；其中营业收入为14.93百万美元，同比减少12.43%，每股基本收益为-1.06美元。从资产负债表来看，Enanta Pharmaceuticals, Inc.总负债2.29亿美元，其中短期债务32.88百万美元，资产负债比为1.42，流动比率为0.06。机构评级：截至2025年5月19日，当前有6家机构对Enanta Pharmaceuticals, Inc.目标价做出预测，其中目标均价为15.50美元，其中最低目标价为5.00美元，最高目标价为23.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ENTA":"Enanta Pharmaceuticals Inc."},"translate_title":"Enanta Pharmaceuticals, Inc. achieved net profit of-US $22.64 million in the first fiscal quarter of fiscal year 2025, a year-on-year increase of 27.34%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENTA":0.9},"content_text":"5月19日，Enanta Pharmaceuticals, Inc.（ENTA.US）公布财报，公告显示公司2025财年第一财季净利润为-22.64百万美元，同比增加27.34%；其中营业收入为14.93百万美元，同比减少12.43%，每股基本收益为-1.06美元。从资产负债表来看，Enanta Pharmaceuticals, Inc.（ENTA.US）总负债2.29亿美元，其中短期债务32.88百万美元，资产负债比为1.42，流动比率为0.06。机构评级：截至2025年5月19日，当前有6家机构对Enanta Pharmaceuticals, Inc.目标价做出预测，其中目标均价为15.50美元，其中最低目标价为5.00美元，最高目标价为23.00美元。公司简介：Enanta Pharmaceuticals Inc是一家美国生物科技公司，利用强大的化学驱动方法和药物发现能力，专注于研发用于治疗病毒感染和肝脏疾病的分子药物。它使用病毒学和免疫学方法治疗疾病。该公司针对的疾病包括丙型肝炎、乙型肝炎、非酒精性脂肪型肝炎和呼吸道合胞病毒。公司研发的新颖之处在于一种用于治疗丙型肝炎病毒的特异性直接作用抗病毒抑制剂。该公司的抑制剂是与艾伯维(AbbVie)合作开发的。艾伯维(AbbVie)销售蛋白酶抑制剂paritaprevir，其他抑制剂正在研发中。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2536459445","isCrawlerRequest":true}